Clinical Trial

Active Thoracic Compromised Distal LANding in TEvar

Study acronym: ATLANTE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2025 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Thoracic endovascular aortic repair (TEVAR) has become the mainstay of aortic intervention for descending thoracic aortic pathology. Its durability hinges on achieving adequate seal in the endograft landing zones (LZs), with the distal LZ largely understudied. Only recently are suboptimal distal LZs receiving attention for their role in major complications including stent graft migration, type 1B endoleaks, and distal stent graft-induced new entry tears, all of which can contribute to further aortic degeneration. The thoracic distal LZ. When a short distal LZ was reported, the distal endoleak rate ranged from 3.5% to 33%. This led to reintervention in 19%, along with coverage of the celiac trunk in more than half of short LZ cases. The objective of this study was to evaluate the outcomes of TEVAR patients with compromised distal landing zone (CDLZs) treated with distal active fixation stent-grafts (DAFs), distal scallop stent-grafts, distal Aptus Heli-FX EndoAnchors, and standard stent-grafts.
Trial Details
NCT Number NCT06882967
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Thoracic Aortic Aneurysm, Aortic Diseases
Enrollment 200 participants
Start Date 2022-11-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-19